Buchumschlag

Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp

Tebentafusp is a new T cell receptor bispecific fusion protein and the first approved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:01) metastatic uveal melanoma, with a proven benefit in overall survival versus the investigator’s choice. As a first-in-class therapeutic option, this...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hassel, Jessica C. (VerfasserIn) , Berking, Carola (VerfasserIn) , Forschner, Andrea (VerfasserIn) , Gebhardt, Christoffer (VerfasserIn) , Heinzerling, Lucie (VerfasserIn) , Meier, Friedegund (VerfasserIn) , Ochsenreither, Sebastian (VerfasserIn) , Siveke, Jens (VerfasserIn) , Hauschild, Axel (VerfasserIn) , Schadendorf, Dirk (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: September 2023
In: European journal of cancer
Year: 2023, Jahrgang: 191, Pages: 1-12
ISSN:1879-0852
DOI:10.1016/j.ejca.2023.112986
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2023.112986
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804923003386
Volltext
Verfasserangaben:Jessica C. Hassel, Carola Berking, Andrea Forschner, Christoffer Gebhardt, Lucie Heinzerling, Friedegund Meier, Sebastian Ochsenreither, Jens Siveke, Axel Hauschild, Dirk Schadendorf
Beschreibung
Zusammenfassung:Tebentafusp is a new T cell receptor bispecific fusion protein and the first approved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:01) metastatic uveal melanoma, with a proven benefit in overall survival versus the investigator’s choice. As a first-in-class therapeutic option, this Immune mobilising monoclonal T cell receptor Against Cancer (ImmTAC) is associated with a new adverse event (AE) profile. Based on clinical experience, a national expert group discussed recommendations for tebentafusp treatment, focusing on AE management. Further topics included prerequisites for initiating tebentafusp treatment, appropriate treatment setting, and patient selection criteria. To provide guidance for treating physicians, the resulting recommendations are summarised including a model standard operating procedure for AE management. Patients in good clinical condition and with a low tumour burden are good candidates for tebentafusp treatment, particularly if treated as early as possible after the diagnosis of metastatic disease. The safety profile of tebentafusp is manageable and includes two major pathologies: cytokine release syndrome (CRS) and skin-related events. Postdose monitoring should thus focus on pyrexia and hypotension as the first symptoms of cytokine release. To minimise the risk of hypotension associated with CRS, patients should receive intravenous fluids before starting treatment. The monitoring of liver values is crucial, as patients may experience an increase in transaminases, which can even manifest as tumour lysis syndrome.
Beschreibung:Online verfügbar: 11. Juli 2023, Artikelversion: 16. August 2023
Gesehen am 08.12.2023
Beschreibung:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2023.112986

Ähnliche Einträge